– Philippines scales its testing capability with two Abbott tests – a quick, patient-friendly rapid antigen test and lab-based quantitative antibody test
– The Abbott Panbio™ COVID-19 Antigen Rapid Test Device comes with an easy-to-use nasal swab to detect active coronavirus infections in as early as 15 minutes at massive scale
– Abbott’s newly introduced lab-based SARS-CoV-2 IgG II quantitative antibody test can help evaluate a person’s immune response to the vaccine
MANILA, April 20, 2021 /PRNewswire/ — Efforts to ramp up COVID-19 testing capacity in the Philippines have received fresh impetus, with the Office of the Civil Defense (OCD) procuring and distributing the Abbott Panbio™ COVID-19 Ag Rapid Test Device for the detection of the SARS-CoV-2 virus in people suspected of having COVID-19. The procurement of 500,000 Panbio rapid antigen tests is part of the OCD’s COVID-19 response to the pandemic and is in addition to purchases by LGUs (Local Government Units) to meet local testing needs. Forty-five hospitals and LGUs in Metro Manila and nearby provinces recently received these tests procured by the OCD.
